AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma | Zendy

Alba A. Brandes | Zendy; Gaetano Finocchiaro | Zendy; Vittorina Zagonel | Zendy; Michele Reni | Zendy; Claudia Caserta | Zendy; Alessandra Fabi | Zendy; Matteo Clavarezza | Zendy; Evaristo Maiello | Zendy; Marica Eoli | Zendy; Giuseppe Lombardi | Zendy; Marta Monteforte | Zendy; Emanuela Proietti | Zendy; R. Agati | Zendy; Vincenzo Eusebi | Zendy; Enrico Franceschi | Zendy

Open Access

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

Author(s) -

Alba A. Brandes,

Gaetano Finocchiaro,

Vittorina Zagonel,

Michele Reni,

Claudia Caserta,

Alessandra Fabi,

Matteo Clavarezza,

Evaristo Maiello,

Marica Eoli,

Giuseppe Lombardi,

Marta Monteforte,

Emanuela Proietti,

R. Agati,

Vincenzo Eusebi,

Enrico Franceschi

Publication year - 2016

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/now035

Subject(s) - bevacizumab , glioblastoma , medicine , randomized controlled trial , oncology , phase (matter) , chemotherapy , cancer research , physics , quantum mechanics

Few prospective studies have assessed the role of bevacizumab and included a control arm with standard treatments for recurrent glioblastoma. We conducted a noncomparative phase II trial (AVAREG) to examine the efficacy of bevacizumab or fotemustine in this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research